المؤلفون: Beckthold B., Kaye S., Land S., Walker S., Haubrich R., DeJesus E., Berthon-Jones N., Espinosa N., Courtney-Vega K., Absar N., Haskelberg H., Robson R., Donaldson A., Guelman D., Tabrett C., Warzywoda E., MacRae K., Sinclair B., Sinn K., Bloch M., Franic T., Vincent T., Stewart N., Jayewardene A., Dwyer D., Kok J., Assam D., Taylor J., King P., Orth D., Youds D., Sowden D., Johnston C., Murray S., Hehir J., Wadham S., Donohue W., Thompson J., Garsia R., Turnham G., Madden T., Nvene J., Gillies A., Bryant M., Walmsley S., Chan W., LeBlanc R., Lanteigne F., Mouawad R., Rahal I., Guber S., Ozturk S., Smith G., Halpenny R., Reko T., Hills J.R., Allendes G., Hocqueloux F.L., Stephan C., Ebeling F., Spath B., Jensen B.-E.O., Feind C., Meyer-Olson D., Stoll M., Hoeper K., Beider R., Faetkenheur G., Thomas E., Baumgarten A., Ingiliz P., Wienbreyer A., Behrendt D., Nienkarken T., Jessen H., Zedlack C., Simelane S., Assmann J., Ghavami-Kia B., Imahashi M., Tanabe K., Yokomaku Y., Imamura J., de Oca M.M., Gonzalez L., Ponce D., Mendoza A., Sierra-Madero J., Hernandez J.E.S., Ballesteros E.J.R., del Moral Ponce S., Ignatowska A., Bakowska E., Pulik P., Sanz-Moreno J., Paredes R., Puig J., Domingo P., Gutierrez M., Gonzalez-Cordon A., Callau P., Aldeguer J.L., Tovar S.C., Noval M.L., Rivas I., Delgado-Fernandez M., Arribas J.R., Castro J.M., Avihingsanon A., Maek-a-nantawat W., Intasan J., Charoenporn W., Cuprasitrut T., Jaisomkom P., Pruksakaew K., Winston A., Mullaney S., Barbour L., Richardson C., Fox J., Murray T., Teague A., Leen C., Morris S., Satyajit D., Sandhu R., Tucker J., Pett S., Amin J., Horban A., Andrade-Villanueva J., Losso M., Porteiro N., Madero J.S., Belloso W., Tu E., Silk D., Kelleher A., Harrigan R., Clark A., Sugiura W., Wolff M.J., Gill J., Gatell J., Clarke A., Ruxrungtham K., Prazuck T., Kaiser R., Woolley I., Alberto Arnaiz J., Cooper D., Rockstroh J.K., Mallon P., Emery S., Fisher M., Rockstroh J., Stellbrink J., Merlin K., Yeung J., Fsadni B., Marks K., Suzuki K., Rismanto N., Salomon H., Rubio A.E., Chibo D., Birch C., Swenson L., Chan D., Berg T., Obermeier M., Schuelter E., Aragon S.S., Luebke N., Coughlan S., Dean J., Iwatani Y., Teran G.R., Avila S., Sirivichayakul S., Naphassanant M., Ubolyam S., Gambardella L., Valdovinos M., Arnaiz J., Beleta H., Ramos N., Targa M., Boesecke C., Engelhardt A., Perry N., Drummond F., Lefevre E., Corr S., Grant C., Lupo S., Peroni L., Sanchez M., De Paz Sierra M., Viloria G., Parlante A., Bissio E., Luchetti P., Confalonieri V., Warley E., Vieni I., Vilas C., Zarate A., Mayer G., Elliot J., Hagenauer M., Kelley M., Rowling D., Gibson A., Latch N.

مصطلحات الفهرس: priority journal, randomized controlled trial, treatment duration, unspecified side effect/si [Side Effect], virology, virus load, abacavir/ct [Clinical Trial], abacavir/cb [Drug Combination], abacavir/cm [Drug Comparison], abacavir/dt [Drug Therapy], atazanavir/ct [Clinical Trial], atazanavir/cb [Drug Combination], cholesterol/ec [Endogenous Compound], lamivudine/ct [Clinical Trial], lamivudine/cb [Drug Combination], lamivudine/cm [Drug Comparison], lamivudine/dt [Drug Therapy], lopinavir/ct [Clinical Trial], lopinavir/cb [Drug Combination], lopinavir/dt [Drug Therapy], low density lipoprotein cholesterol/ec [Endogenous Compound], maraviroc/ae [Adverse Drug Reaction], maraviroc/ct [Clinical Trial], maraviroc/cb [Drug Combination], maraviroc/cm [Drug Comparison], maraviroc/dt [Drug Therapy], ritonavir/ct [Clinical Trial], ritonavir/cb [Drug Combination], ritonavir/cm [Drug Comparison], ritonavir/dt [Drug Therapy], triacylglycerol/ec [Endogenous Compound], virus RNA/ec [Endogenous Compound], atazanavir/dt [Drug Therapy], drug withdrawal, follow up, human, Human immunodeficiency virus 1, Human immunodeficiency virus 1 infection/dt [Drug Therapy], intention to treat analysis, kidney function, longitudinal study, major clinical study, multicenter study, outcome assessment, population, adult, adverse drug reaction, antiretroviral therapy, article, CD4 lymphocyte count, cholesterol blood level, clinical effectiveness, controlled study, drug efficacy, drug safety, drug substitution, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/37141
HIV Medicine
Click here for full text options
LibKey Link

المؤلفون: Beckthold B., Kaye S., Land S., Walker S., Haubrich R., DeJesus E., Berthon-Jones N., Espinosa N., Courtney-Vega K., Absar N., Haskelberg H., Robson R., Donaldson A., Guelman D., Tabrett C., Warzywoda E., MacRae K., Sinclair B., Sinn K., Bloch M., Franic T., Vincent T., Stewart N., Jayewardene A., Dwyer D., Kok J., Assam D., Taylor J., King P., Orth D., Youds D., Sowden D., Johnston C., Murray S., Hehir J., Wadham S., Donohue W., Thompson J., Garsia R., Turnham G., Madden T., Nvene J., Gillies A., Bryant M., Walmsley S., Chan W., LeBlanc R., Lanteigne F., Mouawad R., Rahal I., Guber S., Ozturk S., Smith G., Halpenny R., Reko T., Hills J.R., Allendes G., Hocqueloux F.L., Stephan C., Ebeling F., Spath B., Jensen B.-E.O., Feind C., Meyer-Olson D., Stoll M., Hoeper K., Beider R., Faetkenheur G., Thomas E., Baumgarten A., Ingiliz P., Wienbreyer A., Behrendt D., Nienkarken T., Jessen H., Zedlack C., Simelane S., Assmann J., Ghavami-Kia B., Imahashi M., Tanabe K., Yokomaku Y., Imamura J., de Oca M.M., Gonzalez L., Ponce D., Mendoza A., Sierra-Madero J., Hernandez J.E.S., Ballesteros E.J.R., del Moral Ponce S., Ignatowska A., Bakowska E., Pulik P., Sanz-Moreno J., Paredes R., Puig J., Domingo P., Gutierrez M., Gonzalez-Cordon A., Callau P., Aldeguer J.L., Tovar S.C., Noval M.L., Rivas I., Delgado-Fernandez M., Arribas J.R., Castro J.M., Avihingsanon A., Maek-a-nantawat W., Intasan J., Charoenporn W., Cuprasitrut T., Jaisomkom P., Pruksakaew K., Winston A., Mullaney S., Barbour L., Richardson C., Fox J., Murray T., Teague A., Leen C., Morris S., Satyajit D., Sandhu R., Tucker J., Pett S., Amin J., Horban A., Andrade-Villanueva J., Losso M., Porteiro N., Madero J.S., Belloso W., Tu E., Silk D., Kelleher A., Harrigan R., Clark A., Sugiura W., Wolff M.J., Gill J., Gatell J., Clarke A., Ruxrungtham K., Prazuck T., Kaiser R., Woolley I., Alberto Arnaiz J., Cooper D., Rockstroh J.K., Mallon P., Emery S., Fisher M., Rockstroh J., Stellbrink J., Merlin K., Yeung J., Fsadni B., Marks K., Suzuki K., Rismanto N., Salomon H., Rubio A.E., Chibo D., Birch C., Swenson L., Chan D., Berg T., Obermeier M., Schuelter E., Aragon S.S., Luebke N., Coughlan S., Dean J., Iwatani Y., Teran G.R., Avila S., Sirivichayakul S., Naphassanant M., Ubolyam S., Gambardella L., Valdovinos M., Arnaiz J., Beleta H., Ramos N., Targa M., Boesecke C., Engelhardt A., Perry N., Drummond F., Lefevre E., Corr S., Grant C., Lupo S., Peroni L., Sanchez M., De Paz Sierra M., Viloria G., Parlante A., Bissio E., Luchetti P., Confalonieri V., Warley E., Vieni I., Vilas C., Zarate A., Mayer G., Elliot J., Hagenauer M., Kelley M., Rowling D., Gibson A., Latch N.

مصطلحات الفهرس: priority journal, randomized controlled trial, treatment duration, unspecified side effect/si [Side Effect], virology, virus load, abacavir/ct [Clinical Trial], abacavir/cb [Drug Combination], abacavir/cm [Drug Comparison], abacavir/dt [Drug Therapy], atazanavir/ct [Clinical Trial], atazanavir/cb [Drug Combination], cholesterol/ec [Endogenous Compound], lamivudine/ct [Clinical Trial], lamivudine/cb [Drug Combination], lamivudine/cm [Drug Comparison], lamivudine/dt [Drug Therapy], lopinavir/ct [Clinical Trial], lopinavir/cb [Drug Combination], lopinavir/dt [Drug Therapy], low density lipoprotein cholesterol/ec [Endogenous Compound], maraviroc/ae [Adverse Drug Reaction], maraviroc/ct [Clinical Trial], maraviroc/cb [Drug Combination], maraviroc/cm [Drug Comparison], maraviroc/dt [Drug Therapy], ritonavir/ct [Clinical Trial], ritonavir/cb [Drug Combination], ritonavir/cm [Drug Comparison], ritonavir/dt [Drug Therapy], triacylglycerol/ec [Endogenous Compound], virus RNA/ec [Endogenous Compound], atazanavir/dt [Drug Therapy], drug withdrawal, follow up, human, Human immunodeficiency virus 1, Human immunodeficiency virus 1 infection/dt [Drug Therapy], intention to treat analysis, kidney function, longitudinal study, major clinical study, multicenter study, outcome assessment, population, adult, adverse drug reaction, antiretroviral therapy, article, CD4 lymphocyte count, cholesterol blood level, clinical effectiveness, controlled study, drug efficacy, drug safety, drug substitution, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/37141
HIV Medicine
Click here for full text options
LibKey Link

المؤلفون: Bowden S., Le S., Giles M., Sasaduesz J., Cowie B., Strasser S., Levy M., Visvanathan K., Dusheiko G., Wong M.-L., Phung N., Walker S., Lim S.G., Gane E., Ngu M., Hardikar W.

مصطلحات الفهرس: patient referral, pregnancy outcome, pregnant woman, prenatal screening, priority journal, puerperium, United Kingdom, vaccination, vertical transmission, virus load, virus transmission, adefovir/dt [Drug Therapy], adefovir/to [Drug Toxicity], entecavir/dt [Drug Therapy], entecavir/to [Drug Toxicity], hepatitis B antibody/ct [Clinical Trial], hepatitis B antibody/cb [Drug Combination], hepatitis B antibody/dt [Drug Therapy], hepatitis B surface antigen/ec [Endogenous Compound], hepatitis B vaccine/ct [Clinical Trial], hepatitis B vaccine/cb [Drug Combination], hepatitis B vaccine/dt [Drug Therapy], lamivudine/ct [Clinical Trial], lamivudine/cm [Drug Comparison], lamivudine/cr [Drug Concentration], lamivudine/dt [Drug Therapy], lamivudine/to [Drug Toxicity], peginterferon/dt [Drug Therapy], peginterferon alpha2a/dt [Drug Therapy], peginterferon alpha2a/to [Drug Toxicity], placebo, telbivudine/cm [Drug Comparison], telbivudine/dt [Drug Therapy], telbivudine/to [Drug Toxicity], tenofovir/ct [Clinical Trial], tenofovir/cr [Drug Concentration], tenofovir/dt [Drug Therapy], tenofovir/to [Drug Toxicity], tenofovir/sc [Subcutaneous Drug Administration], tenofovir alafenamide/cm [Drug Comparison], tenofovir alafenamide/po [Oral Drug Administration], tenofovir disoproxil/cm [Drug Comparison], tenofovir disoproxil/dt [Drug Therapy], tenofovir disoproxil/po [Oral Drug Administration], virus DNA, virus fusion inhibitor/dt [Drug Therapy], tenofovir disoproxil/cr [Drug Concentration], antiviral resistance, antiviral therapy, article, Australia, breast feeding, chronic hepatitis B/dt [Drug Therapy], disease exacerbation, drug blood level, drug milk level, drug safety, drug substitution, drug withdrawal, embryotoxicity, family planning, fetus malformation, follow up, hepatitis B/dr [Drug Resistance], hepatitis B/dt [Drug Therapy], hepatitis B/pc [Prevention], human, Human immunodeficiency virus infection/dt [Drug Therapy], immunoprophylaxis, liver fibrosis, New Zealand, nonhuman, obstetric procedure, patient education, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/40050
Gut
Click here for full text options
LibKey Link

المؤلفون: Klassen K.M., Fairley C.K., Emery S., Anderson P.H., Ebeling P.R., Kimlin M.G.

مصطلحات الفهرس: lumbar spine, major clinical study, male, obesity, osteopenia, outcome assessment, priority journal, randomized controlled trial (topic), treatment duration, virus replication, vitamin D deficiency, winter, 25 hydroxyvitamin D/ec [Endogenous Compound], abacavir plus lamivudine/ct [Clinical Trial], abacavir plus lamivudine/dt [Drug Therapy], alkaline phosphatase/ec [Endogenous Compound], calcitriol/ec [Endogenous Compound], calcium/ec [Endogenous Compound], emtricitabine/ct [Clinical Trial], emtricitabine/cb [Drug Combination], emtricitabine/dt [Drug Therapy], tenofovir/ct [Clinical Trial], emtricitabine plus tenofovir/dt [Drug Therapy], osteoporosis, tenofovir/cb [Drug Combination], tenofovir/dt [Drug Therapy], unclassified drug, emtricitabine plus tenofovir/ct [Clinical Trial], adult, article, body mass, bone density, bone turnover, calcium blood level, Caucasian, dual energy X ray absorptiometry, ethnicity, female, hip, human, Human immunodeficiency virus infection/dt [Drug Therapy], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/39604
Osteoporosis International
Click here for full text options
LibKey Link

المؤلفون: Bowden S., Le S., Giles M., Sasaduesz J., Cowie B., Strasser S., Levy M., Visvanathan K., Dusheiko G., Wong M.-L., Phung N., Walker S., Lim S.G., Gane E., Ngu M., Hardikar W.

مصطلحات الفهرس: patient referral, pregnancy outcome, pregnant woman, prenatal screening, priority journal, puerperium, United Kingdom, vaccination, vertical transmission, virus load, virus transmission, adefovir/dt [Drug Therapy], adefovir/to [Drug Toxicity], entecavir/dt [Drug Therapy], entecavir/to [Drug Toxicity], hepatitis B antibody/ct [Clinical Trial], hepatitis B antibody/cb [Drug Combination], hepatitis B antibody/dt [Drug Therapy], hepatitis B surface antigen/ec [Endogenous Compound], hepatitis B vaccine/ct [Clinical Trial], hepatitis B vaccine/cb [Drug Combination], hepatitis B vaccine/dt [Drug Therapy], lamivudine/ct [Clinical Trial], lamivudine/cm [Drug Comparison], lamivudine/cr [Drug Concentration], lamivudine/dt [Drug Therapy], lamivudine/to [Drug Toxicity], peginterferon/dt [Drug Therapy], peginterferon alpha2a/dt [Drug Therapy], peginterferon alpha2a/to [Drug Toxicity], placebo, telbivudine/cm [Drug Comparison], telbivudine/dt [Drug Therapy], telbivudine/to [Drug Toxicity], tenofovir/ct [Clinical Trial], tenofovir/cr [Drug Concentration], tenofovir/dt [Drug Therapy], tenofovir/to [Drug Toxicity], tenofovir/sc [Subcutaneous Drug Administration], tenofovir alafenamide/cm [Drug Comparison], tenofovir alafenamide/po [Oral Drug Administration], tenofovir disoproxil/cm [Drug Comparison], tenofovir disoproxil/dt [Drug Therapy], tenofovir disoproxil/po [Oral Drug Administration], virus DNA, virus fusion inhibitor/dt [Drug Therapy], tenofovir disoproxil/cr [Drug Concentration], antiviral resistance, antiviral therapy, article, Australia, breast feeding, chronic hepatitis B/dt [Drug Therapy], disease exacerbation, drug blood level, drug milk level, drug safety, drug substitution, drug withdrawal, embryotoxicity, family planning, fetus malformation, follow up, hepatitis B/dr [Drug Resistance], hepatitis B/dt [Drug Therapy], hepatitis B/pc [Prevention], human, Human immunodeficiency virus infection/dt [Drug Therapy], immunoprophylaxis, liver fibrosis, New Zealand, nonhuman, obstetric procedure, patient education, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/40050
Gut
LibKey Link

المؤلفون: Klassen K.M., Fairley C.K., Emery S., Anderson P.H., Ebeling P.R., Kimlin M.G.

مصطلحات الفهرس: lumbar spine, major clinical study, male, obesity, osteopenia, outcome assessment, priority journal, randomized controlled trial (topic), treatment duration, virus replication, vitamin D deficiency, winter, 25 hydroxyvitamin D/ec [Endogenous Compound], abacavir plus lamivudine/ct [Clinical Trial], abacavir plus lamivudine/dt [Drug Therapy], alkaline phosphatase/ec [Endogenous Compound], calcitriol/ec [Endogenous Compound], calcium/ec [Endogenous Compound], emtricitabine/ct [Clinical Trial], emtricitabine/cb [Drug Combination], emtricitabine/dt [Drug Therapy], tenofovir/ct [Clinical Trial], emtricitabine plus tenofovir/dt [Drug Therapy], osteoporosis, tenofovir/cb [Drug Combination], tenofovir/dt [Drug Therapy], unclassified drug, emtricitabine plus tenofovir/ct [Clinical Trial], adult, article, body mass, bone density, bone turnover, calcium blood level, Caucasian, dual energy X ray absorptiometry, ethnicity, female, hip, human, Human immunodeficiency virus infection/dt [Drug Therapy], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/39604
Osteoporosis International
LibKey Link

المؤلفون: Ratnam D., Angus P.

مصطلحات الفهرس: hepatitis B/dt [Drug Therapy], hepatitis B/pc [Prevention], human, hyperthyroidism/dt [Drug Therapy], hyperthyroidism/si [Side Effect], liver cell carcinoma, liver cirrhosis, liver fibrosis, low drug dose, multidrug resistance, patient compliance, pneumonia/si [Side Effect], review, thrombocytopenia/si [Side Effect], virus load, adefovir/ct [Clinical Trial], adefovir/cb [Drug Combination], adefovir/dt [Drug Therapy], alanine aminotransferase/ec [Endogenous Compound], carbimazole/dt [Drug Therapy], entecavir/dt [Drug Therapy], hepatitis B antibody/cb [Drug Combination], hepatitis B antibody/dt [Drug Therapy], hepatitis B(e) antigen/ec [Endogenous Compound], lamivudine/ct [Clinical Trial], lamivudine/cb [Drug Combination], lamivudine/dt [Drug Therapy], peginterferon/ae [Adverse Drug Reaction], peginterferon/ct [Clinical Trial], peginterferon/dt [Drug Therapy], tenofovir/ct [Clinical Trial], tenofovir/cb [Drug Combination], tenofovir/dt [Drug Therapy], seroconversion, antiviral resistance, antiviral therapy, Australia, drug efficacy, drug fever/si [Side Effect], drug induced headache/si [Side Effect], drug potency, drug substitution, drug tolerability, drug withdrawal, fatigue/si [Side Effect], gastrointestinal hemorrhage/si [Side Effect], hepatitis B/dr [Drug Resistance], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28370
Click here for full text options
LibKey Link

المؤلفون: Ratnam D., Angus P.

مصطلحات الفهرس: hepatitis B/dt [Drug Therapy], hepatitis B/pc [Prevention], human, hyperthyroidism/dt [Drug Therapy], hyperthyroidism/si [Side Effect], liver cell carcinoma, liver cirrhosis, liver fibrosis, low drug dose, multidrug resistance, patient compliance, pneumonia/si [Side Effect], review, thrombocytopenia/si [Side Effect], virus load, adefovir/ct [Clinical Trial], adefovir/cb [Drug Combination], adefovir/dt [Drug Therapy], alanine aminotransferase/ec [Endogenous Compound], carbimazole/dt [Drug Therapy], entecavir/dt [Drug Therapy], hepatitis B antibody/cb [Drug Combination], hepatitis B antibody/dt [Drug Therapy], hepatitis B(e) antigen/ec [Endogenous Compound], lamivudine/ct [Clinical Trial], lamivudine/cb [Drug Combination], lamivudine/dt [Drug Therapy], peginterferon/ae [Adverse Drug Reaction], peginterferon/ct [Clinical Trial], peginterferon/dt [Drug Therapy], tenofovir/ct [Clinical Trial], tenofovir/cb [Drug Combination], tenofovir/dt [Drug Therapy], seroconversion, antiviral resistance, antiviral therapy, Australia, drug efficacy, drug fever/si [Side Effect], drug induced headache/si [Side Effect], drug potency, drug substitution, drug tolerability, drug withdrawal, fatigue/si [Side Effect], gastrointestinal hemorrhage/si [Side Effect], hepatitis B/dr [Drug Resistance], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28370
LibKey Link

المؤلفون: Pangerl A., Beebe S., Yu M., Wongcharatrawee S., Manns M.P., Akarca U.S., Chang T.-T., Sievert W., Yoon S.K., Tsai N., Min A.

مصطلحات الفهرس: gastroenteritis/si [Side Effect], hepatitis B/dt [Drug Therapy], human, hydronephrosis/si [Side Effect], hypertension/si [Side Effect], hypophosphatemia/si [Side Effect], inguinal hernia/si [Side Effect], insomnia/si [Side Effect], lactate blood level, liver cell carcinoma/si [Side Effect], liver function test, lymphoproliferative disease/si [Side Effect], monotherapy, muscle weakness/si [Side Effect], myalgia/si [Side Effect], nausea/si [Side Effect], osteoporosis/si [Side Effect], pancreatitis/si [Side Effect], paresthesia/si [Side Effect], perianal abscess/si [Side Effect], phase 3 clinical trial (topic), pneumonia/si [Side Effect], polymerase chain reaction, polyneuropathy/si [Side Effect], randomized controlled trial (topic), relapse, restless legs syndrome/si [Side Effect], rhinopharyngitis/si [Side Effect], side effect/si [Side Effect], thrombocytopenia/si [Side Effect], treatment response, triacylglycerol lipase blood level, upper abdominal pain/si [Side Effect], upper respiratory tract infection/si [Side Effect], adefovir/ct [Clinical Trial], adefovir/cm [Drug Comparison], adefovir/dt [Drug Therapy], alanine aminotransferase/ec [Endogenous Compound], alpha interferon/dt [Drug Therapy], aspartate aminotransferase/ec [Endogenous Compound], bicarbonate/ec [Endogenous Compound], creatine kinase/ec [Endogenous Compound], creatinine/ec [Endogenous Compound], entecavir/ae [Adverse Drug Reaction], entecavir/ct [Clinical Trial], entecavir/cb [Drug Combination], entecavir/cm [Drug Comparison], entecavir/dt [Drug Therapy], entecavir/to [Drug Toxicity], hepatitis B(e) antigen, lactic acid/ec [Endogenous Compound], lamivudine/ae [Adverse Drug Reaction], lamivudine/ct [Clinical Trial], lamivudine/cb [Drug Combination], lamivudine/dt [Drug Therapy], triacylglycerol lipase/ec [Endogenous Compound], phase 2 clinical trial (topic), alanine aminotransferase blood level, alopecia/si [Side Effect], antiviral therapy, appendicitis/si [Side Effect], article, aspartate aminotransferase blood level, bicarbonate blood level, cellulitis/si [Side Effect], creatine kinase blood level, creatinine blood level, decompensated liver cirrhosis/si [Side Effect], diarrhea/si [Side Effect], disease course, dizziness/si [Side Effect], drug eruption/si [Side Effect], drug exposure, drug induced headache/si [Side Effect], drug safety, drug tolerability, drug withdrawal, fatigue/si [Side Effect], gallstone/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28206
Click here for full text options
LibKey Link

المؤلفون: Emery S., Cooper D.A., Carr A., Kelleher A.D., Bloch M., Baker D., Woolley I., Martin A., Amin J.

مصطلحات الفهرس: cardiovascular disease, cardiovascular risk, clinical trial, comparative study, controlled clinical trial, disease marker, female, hazard ratio, highly active antiretroviral therapy, human, Human immunodeficiency virus infected patient, Human immunodeficiency virus infection/dt [Drug Therapy], kidney function, major clinical study, male, morbidity, mortality, pathophysiology, phase 4 clinical trial, priority journal, randomized controlled trial, thrombocyte function, abacavir plus lamivudine/ct [Clinical Trial], abacavir plus lamivudine/cm [Drug Comparison], abacavir plus lamivudine/dt [Drug Therapy], alpha interferon/ec [Endogenous Compound], biological marker, C reactive protein/ec [Endogenous Compound], cystatin C/ec [Endogenous Compound], D dimer/ec [Endogenous Compound], emtricitabine plus tenofovir disoproxil/ct [Clinical Trial], emtricitabine plus tenofovir disoproxil/cm [Drug Comparison], emtricitabine plus tenofovir disoproxil/dt [Drug Therapy], fibrinogen/ec [Endogenous Compound], intercellular adhesion molecule 1/ec [Endogenous Compound], interleukin 10/ec [Endogenous Compound], interleukin 6/ec [Endogenous Compound], macrophage migration inhibition factor/ec [Endogenous Compound], PADGEM protein/ec [Endogenous Compound], serum amyloid A/ec [Endogenous Compound], serum amyloid P/ec [Endogenous Compound], vascular cell adhesion molecule 1/ec [Endogenous Compound], multicenter study, adult, article, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/30960
LibKey Link

المؤلفون: Pangerl A., Beebe S., Yu M., Wongcharatrawee S., Manns M.P., Akarca U.S., Chang T.-T., Sievert W., Yoon S.K., Tsai N., Min A.

مصطلحات الفهرس: gastroenteritis/si [Side Effect], hepatitis B/dt [Drug Therapy], human, hydronephrosis/si [Side Effect], hypertension/si [Side Effect], hypophosphatemia/si [Side Effect], inguinal hernia/si [Side Effect], insomnia/si [Side Effect], lactate blood level, liver cell carcinoma/si [Side Effect], liver function test, lymphoproliferative disease/si [Side Effect], monotherapy, muscle weakness/si [Side Effect], myalgia/si [Side Effect], nausea/si [Side Effect], osteoporosis/si [Side Effect], pancreatitis/si [Side Effect], paresthesia/si [Side Effect], perianal abscess/si [Side Effect], phase 3 clinical trial (topic), pneumonia/si [Side Effect], polymerase chain reaction, polyneuropathy/si [Side Effect], randomized controlled trial (topic), relapse, restless legs syndrome/si [Side Effect], rhinopharyngitis/si [Side Effect], side effect/si [Side Effect], thrombocytopenia/si [Side Effect], treatment response, triacylglycerol lipase blood level, upper abdominal pain/si [Side Effect], upper respiratory tract infection/si [Side Effect], adefovir/ct [Clinical Trial], adefovir/cm [Drug Comparison], adefovir/dt [Drug Therapy], alanine aminotransferase/ec [Endogenous Compound], alpha interferon/dt [Drug Therapy], aspartate aminotransferase/ec [Endogenous Compound], bicarbonate/ec [Endogenous Compound], creatine kinase/ec [Endogenous Compound], creatinine/ec [Endogenous Compound], entecavir/ae [Adverse Drug Reaction], entecavir/ct [Clinical Trial], entecavir/cb [Drug Combination], entecavir/cm [Drug Comparison], entecavir/dt [Drug Therapy], entecavir/to [Drug Toxicity], hepatitis B(e) antigen, lactic acid/ec [Endogenous Compound], lamivudine/ae [Adverse Drug Reaction], lamivudine/ct [Clinical Trial], lamivudine/cb [Drug Combination], lamivudine/dt [Drug Therapy], triacylglycerol lipase/ec [Endogenous Compound], phase 2 clinical trial (topic), alanine aminotransferase blood level, alopecia/si [Side Effect], antiviral therapy, appendicitis/si [Side Effect], article, aspartate aminotransferase blood level, bicarbonate blood level, cellulitis/si [Side Effect], creatine kinase blood level, creatinine blood level, decompensated liver cirrhosis/si [Side Effect], diarrhea/si [Side Effect], disease course, dizziness/si [Side Effect], drug eruption/si [Side Effect], drug exposure, drug induced headache/si [Side Effect], drug safety, drug tolerability, drug withdrawal, fatigue/si [Side Effect], gallstone/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28206
LibKey Link